AUSTIN, Texas — August 27, 2025 — BiotechReporter.news — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO John Climaco discussed novel treatments for brain and central nervous system cancers on The BioMedWire Podcast. The interview highlights CNS Pharmaceuticals’ commitment to changing the outlook for patients facing glioblastoma.
Climaco explained the difficulties in treating cancers behind the blood-brain barrier. He noted the company repurposed its clinical infrastructure to accelerate the development of its TPI 287 program after facing challenges in its berubicin trial.
Looking ahead, Climaco outlined the company’s ambitions in underserved cancer markets and highlighted the potential for drugs like berubicin and TPI 287 in both primary brain cancer and metastatic settings. The podcast episode is available at https://podcast.biomedwire.com.
Contact:
IBN
Austin, Texas
Editor@InvestorBrandNetwork.com
512.354.7000
Source: IBN
